Further studies are needed to compare the chimeric to the pseudotype PrP VLP vaccine and determine the potential of a PrP-VLP vaccine for prophylactic or even therapeutic interventions in currently fatal and incurable prion diseases. This evidence concerns the gene PRNP and prion disease.